{"id":"W4408979741","doi":"10.1016/s1556-0864(25)00329-6","title":"134TiP: Evaluation of an additional cohort of patients with non-small cell lung cancer (NSCLC) in the phase I/II duravelo-1 study of zelenectide pevedotin (BT8009), a bicycle toxin conjugate","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Sierra Oncology; Ipsen; Daiichi Sankyo Europe; Servier; Genentech; Institut Gustave-Roussy; European Society for Medical Oncology; Basilea Pharmaceutica; Eisai; Incyte; Boston Pharmaceuticals; Seagen; Agios Pharmaceuticals; Eisai Canada; Cholangiocarcinoma Foundation; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Celldex Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; Bayer HealthCare; Sanofi; Exelixis; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Celgene; Amgen","keywords":"Medicine; Conjugate; Oncology; Lung cancer; Cohort; Internal medicine; Toxin; Microbiology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007231678,0.001231979,0.00105083,0.000328567,0.0005298121,0.001065718,0.0006513082,0.0008017493,0.004567174],"category_scores_gemma":[0.0007572056,0.0003423762,0.001035026,0.0003633631,0.0003981203,0.0006714183,0.0005326865,0.001205275,0.001717942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006224434,"about_ca_system_score_gemma":0.0006808661,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009472431,"about_ca_topic_score_gemma":0.001543894,"domain_scores_codex":[0.9995989,0.00009407588,0.00001985835,0.0001479954,0.00004339548,0.00009577669],"domain_scores_gemma":[0.9996065,0.00005147221,0.00006533547,0.00005299941,0.00005072072,0.000172966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2907122,0.0122485,0.5203453,0.0004642441,0.002012146,0.001602877,0.0004957907,0.001303905,0.07171897,0.000393298,0.01018412,0.0885186],"study_design_scores_gemma":[0.05275298,0.1412529,0.7730417,0.00004124335,0.002141497,0.003406627,0.0005434324,0.002556794,0.00791721,0.0004826582,0.01576428,0.00009872746],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956824,0.0002588064,0.0002482041,0.0001207978,0.00004410558,0.0002464213,0.002291615,0.00003494717,0.00107259],"genre_scores_gemma":[0.9794697,0.0002934873,0.000813163,0.0005898828,0.0001545956,0.000599387,0.01534132,0.00003385447,0.002704653],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004567174,"threshold_uncertainty_score":0.0152787,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0175343280919564,"score_gpt":0.4362063720962736,"score_spread":0.4186720440043171,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}